We have closed an investment, in a $7m funding round, in Sphere Fluidics for the University of Cambridge Enterprise Fund III. This follows the UCEFs I and II investing previously. The investment round has been led by an Asian corporate investor

Sphere Fluidics is an established Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.

The company was founded on IP generated by the University of Cambridge and has in-licensed 10 patent families from the University and other leading institutions. The core technology is now protected by 51 patents and has been developed with equity and over £7m of grants.